Senti Biosciences Holdings, Inc. Earnings Per Share Disclosure
| Years Ended December 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Net loss from continuing operations | $ | (52,790) | $ | (83,406) | ||||||||||
| Net income from discontinued operations | — | 12,348 | ||||||||||||
| Accretion for Series A redeemable convertible preferred stock | $ | (2,522) | $ | — | ||||||||||
| Net loss | $ | (55,312) | $ | (71,058) | ||||||||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 4,595,946 | 4,437,106 | ||||||||||||
| Net loss per share from continuing operations, basic and diluted | $ | (12.03) | (18.80) | |||||||||||
| Net income (loss) per share from discontinued operations, basic and diluted | — | 2.79 | ||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (12.03) | $ | (16.01) | ||||||||||
| Years Ended December 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Series A redeemable convertible preferred stock | 21,157,000 | — | ||||||||||||
| Stock options to purchase common stock | 1,333,030 | 1,158,294 | ||||||||||||
| Unvested early exercised options | 422 | 5,486 | ||||||||||||
| Restricted stock units outstanding | 56,423 | 22,528 | ||||||||||||
| Performance stock units outstanding | 106,806 | — | ||||||||||||
| Contingent earnout common stock | 100,000 | 200,000 | ||||||||||||
| Warrants to purchase common stock issued in connection with Series A redeemable convertible preferred stock | 31,735,500 | — | ||||||||||||
| GeneFab Option (Note 3) | 1,963,344 | 1,963,344 | ||||||||||||
| Total | 56,452,525 | 3,349,652 | ||||||||||||
Want the next Senti Biosciences Holdings, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Senti Biosciences Holdings, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 20, 2025 | Showing above |
| 2023 | Mar 21, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.